Polar End-Capping - General-Purpose ODS Column
FEATURES
Balanced universal ODS stationary phase for compounds ranging from high to low polarity
Excellent Response for Basic Compounds in Formic Acid Mobile Phase
Superior stereoselectivity and separation performance of isomers
User-friendly high-theoretical-plate columns with 3 μm (CX-C18) and 5 μm (5CX-C18) particles
Wide Range of Column Sizes: Inner Diameter 0.075 - 28mm / Length 10 - 500mm
MAIN SPECIFICATIONS
| Particle size: | 3μm (Cadenza CX-C18) 5μm (Cadenza 5CX-C18) |
| Base material: | Fully Porous High-Purity Silica Gel |
| Pore size: | 12nm |
| Ligand: | Octadecyl group |
| End-capping: | Polar Group End-Capping |
| Target molecular weight: | Below 10kDa |
| pH range: | pH 2-10 |
| Maximum pressure: | 250bar / 3,500psi / 25MPa HP: 500bar / 7,500psi / 50MPa, UP: 1,000bar / 15,000psi / 100MPa |
| USP Code: | L1 |
Traditional silica-based ODS columns containing hybrid silica require "end-capping" to reduce "residual silanol groups" remaining on the silica surface after introducing the octadecyl group. Traditionally, surface treatment methods using methylsilane compounds have been employed.
However, from the perspective of reversed-phase separation, the silica surface ends up with two types of hydrophobic groups: those derived from ODS ligands and those from end-capping, which can result in uneven hydrophobic interactions. This can adversely affect peak shapes and theoretical plate numbers.
Instead of using classical methylsilane end-capping, such as trimethylsilyl groups (TMS), an innovative end-capping method using polar groups (ethers, hydroxyl groups) has been developed and applied to Cadenza CX-C18. The hydrophobic groups of solutes primarily interact with the octadecyl groups (ODS), while the hydrophilic groups interact electrostatically with the polar group end-capping structures.
As a result, improvements in peak shape and theoretical plate number for highly hydrophobic strong basic compounds are expected.
Additionally, the spatial localization of hydrophobic/hydrophilic groups on the stationary phase surface may enhance the recognition of solute stereostructures, potentially leading to separation characteristics distinct from traditional columns.
Cadenza CX-C18 with this novel end-capping method expands the world of versatile reversed-phase separation.
Technical Information
Applications NEW
Basic Compounds
- ● Thiazolyl Blue Tetrazolium (MTT Assay) Column Comparison NEW
- ● Dobutamine (Cardiotonic)
- ● Column Comparison: Bupropion (Antidepressant)
- ● Column Comparison: Triphenylphosphonium (Condensed Organic Catalyst)
- ● Pentafluoroanilinium (Condensed Organic Catalyst)
- ● Donepezil (Agents for alzheimer-type dementia)
- ● Aripiprazole (Antipsychotic agent)
- ● Coumarin 153 (Organic EL Material)
- ● Bicarbazole (Organic EL Material)
- ● Carbazolyltriphenylamine (Organic EL Material)
- ● Carbazolylbenzene (Organic EL Material)
- ● Biphenyl Triazine (Organic EL Material)
- ● Erythromycin and derivatives (Antibiotics)
- ● Rasagiline (Antiparkinsonian drug)
- ● Venlafaxine (Antidepressant)
- ● Mirtazapine (Antidepressant)
- ● Brucine (Indole alkaloid)
- ● Furan derivatives
- ● Chlorhexidine (Antibacterial)
- ● Papaverine (Vasodilator)
- ● Loratadine (Antiallergic agent)
- ● Nystatin (Polyene macrolide antibiotic)
- ● Guanfacine (Antihypertensive)
- ● Chlorhexidine (Antibacterial)
- ● Quinidine (Antiarrhythmic)
- ● Photopolymerization Initiator
- ● Trimebutine (Gastrointestinal Drug)
- ● Melatonin-related Compounds MS
- ● Sibutramine (Appetite Suppressant) MS
- ● Sibutramine (Appetite Suppressant) Column Comparison
- ● Ambroxol (Expectorant)
- ● Aprepitant (Anti-emetic)
- ● Desloratadine (Histamine Receptor Antagonist)
- ● Didecyldimethylammonium Chloride (Disinfectant) MS
- ● N,N"-Diphenylethylenediamine (Nitrogen-containing Ligand)
- ● Pinaverium (Antispasmodic) Column Comparison
- ● Clarithromycin (Macrolide Antibiotic)
- ● HMMM (Hexamethoxymethylmelamine Resin Hardener, Rubber Additive) MS
- ● PPDs (Rubber Antioxidant, Amine-based Antioxidant)
- ● Ifenprodil (Peripheral Vasodilator) MS
- ● Doxycycline (Antibiotic) MS
- ● Triazine Herbicides MS
- ● Fexofenadine (Allergy Rhinitis Drug)
- ● Mosapride (Gastrointestinal Motility Improver)
- ● Raloxifene (Osteoporosis Treatment)
- ● Loperamide (Antidiarrheal, Opioid Receptor Agonist)
- ● Lomerizine (Migraine Treatment, Calcium Antagonist)
- ● Bromhexine (Expectorant)
- ● Cetylpyridinium Chloride
- ● Antiviral Drugs (Remdesivir)
- ● Rheumatoid Arthritis Drugs (Tofacitinib, Filgotinib)
- ● Levofloxacin (Fluoroquinolone Antibiotic) Elution Comparison
- ● Tadalafil (PDE-5 Inhibitor) Elution Comparison
- ● Eperisone (Antispasmodic) Elution Comparison
- ● Ractopamine (Veterinary Drug) Elution Comparison
- ● Separation Comparison of Aliphatic Amines
- ● Separation Comparison of Cold Medicine Ingredients (Dextromethorphan)
- ● Basic Compounds in Formic Acid Acidic Mobile Phase
- ● Basic Compounds in Formic Acid Acidic Mobile Phase MS
- ● Separation Comparison of Alkaloids MS
- ● Berberine in Coptis Rhizome Powder MS
Acidic Compounds
Isomers, Analogues, and Impurity Separations
- ● Donor building block for organic semiconductor (Halogenated ethylenedioxythiophene analogues)
- ● Simultaneous Separation of Quinolone Antibiotics MS
- ● Simultaneous Separation of Quinolone Antibiotics
- ● Acetaminophen and Metabolites
- ● Doxepin Isomers MS
- ● Isomers (Parabens) Separation Comparison
- ● PFAS Separation Comparison MS
- ● Benzodiazepine Anxiolytics (Diazepam)
- ● Troxerutin (Vascular Protector)
Peak Shape and Other Aspects